Pediatric eosinophilic gastritis treated with benralizumab: A case report

JPGN Reports Pub Date : 2024-06-14 DOI:10.1002/jpr3.12088
D. Cheung, Dawn Ebach, Benjamin Davis
{"title":"Pediatric eosinophilic gastritis treated with benralizumab: A case report","authors":"D. Cheung, Dawn Ebach, Benjamin Davis","doi":"10.1002/jpr3.12088","DOIUrl":null,"url":null,"abstract":"We report one of the first cases of eosinophilic gastritis (EoG) in a child under 12 years treated with benralizumab. At 7 years, our patient was started on benralizumab after failing to respond to various combinations of high‐dose omeprazole, milk elimination diet, oral viscous budesonide, and oral systemic steroids. He had a complete depletion of gastrointestinal tissue eosinophils with improved symptoms but had symptomatic flares with tapering of background therapy. However, after 4 years on benralizumab he became symptomatic again. Benralizumab may be a viable option for EoG refractory to systemic steroids but only as a short‐term adjunct therapy. More robust studies with long‐term data are needed, especially in this younger population.","PeriodicalId":17618,"journal":{"name":"JPGN Reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JPGN Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/jpr3.12088","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

We report one of the first cases of eosinophilic gastritis (EoG) in a child under 12 years treated with benralizumab. At 7 years, our patient was started on benralizumab after failing to respond to various combinations of high‐dose omeprazole, milk elimination diet, oral viscous budesonide, and oral systemic steroids. He had a complete depletion of gastrointestinal tissue eosinophils with improved symptoms but had symptomatic flares with tapering of background therapy. However, after 4 years on benralizumab he became symptomatic again. Benralizumab may be a viable option for EoG refractory to systemic steroids but only as a short‐term adjunct therapy. More robust studies with long‐term data are needed, especially in this younger population.
使用苯拉利珠单抗治疗小儿嗜酸性粒细胞性胃炎:病例报告
我们报告了首例使用苯拉利珠单抗治疗 12 岁以下儿童嗜酸性粒细胞性胃炎(EoG)的病例。患者在 7 岁时开始使用苯拉利珠单抗,此前他曾接受过大剂量奥美拉唑、牛奶排除饮食、口服粘稠布地奈德和口服全身性类固醇等多种治疗组合,但均无效。他的胃肠道组织嗜酸性粒细胞被完全清除,症状有所改善,但在减少背景治疗后症状复发。然而,在服用苯拉利珠单抗 4 年后,他又出现了症状。本拉珠单抗可能是治疗全身类固醇难治性嗜酸性粒细胞增多症的可行方案,但只能作为短期辅助疗法。我们需要更多具有长期数据的可靠研究,尤其是针对年轻患者的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信